Piper Sandler Maintains Overweight on ALX Oncology Holdings, Raises Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond has maintained an Overweight rating on ALX Oncology Holdings (NASDAQ:ALXO) and increased the price target from $11 to $21.
March 08, 2024 | 1:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reaffirmed its Overweight rating on ALX Oncology Holdings and raised its price target from $11 to $21.
The increase in price target by a reputable analyst like Christopher Raymond suggests a strong bullish outlook on ALX Oncology Holdings. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100